Pfizer Inc. (0Q1N.IL)
| Previous close | 26.50 |
| Open | 27.16 |
| Bid | 26.40 x N/A |
| Ask | 28.40 x N/A |
| Day's range | 27.05 - 27.16 |
| 52-week range | 25.21 - 41.20 |
| Volume | |
| Avg. volume | 299,657 |
| Market cap | 164.314B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 7.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.64 (5.31%) |
| Ex-dividend date | 08 Nov 2023 |
| 1y target est | N/A |
- Business Wire
Pfizer Reports First-Quarter 2024 Results
NEW YORK, May 01, 2024--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6).
- Business Wire
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
- Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
